CRISPR Therapeutics Vertex Pharmaceuticals: Better Buy in 2026
Investors face a choice between a high-growth gene-editing bet and a cash-generating biotech leader. This article bre...
Understanding when to shift from stocks to bonds can enhance your investment strategy. Make informed decisions to maximize returns.
22,202 articlesInvestors face a choice between a high-growth gene-editing bet and a cash-generating biotech leader. This article bre...
Lincoln Financial is positioned as a stable anchor for retirement, while three Miller-style bets—Strategy, Nabors, an...
Two very different approaches to growth: Nvidia leads AI hardware and software, while Strategy blends software with B...
A new market note lays out an upside case for SpaceX, predicting an 87% rally on the back of quick index inclusion an...
Tesla reports a record-breaking Q2, delivering 480,126 vehicles and signaling renewed momentum. Regional strength in ...
For years, SK Hynix has traded at a discount to Micron. This article explains why the gap exists, what could close it...
Rivian stock fell first half 2026 as a mix of delivery updates, new model momentum, and macro headwinds shaped invest...
Nuclear expansion plans are accelerating, and uranium ETFs are drawing fresh attention. A look at URA, URNM, URNJ, NL...
A FormFactor director recently sold 3,000 shares in a move that drew attention from investors. This article breaks do...
Argentina presses ahead with sweeping reforms, betting on privatizations and tighter budgets. Investors are turning t...
The Metals Company aims to unlock a vast resource of nickel, cobalt, copper, and manganese. In 2026, whether it’s a b...
Cathie Wood's Ark Invest has stepped in with notable dip buys on Coinbase and Robinhood, helping both names rebound. ...